Biohaven Ltd. (BHVN)
15.30
+0.82
(+5.70%)
USD |
NYSE |
Nov 09, 11:48
Biohaven Debt to Equity Ratio : -3.058 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | -3.058 |
| June 30, 2026 | 24.30 |
| March 31, 2026 | 2.210 |
| December 31, 2025 | 5.466 |
| September 30, 2025 | -18.31 |
| June 30, 2025 | 2.166 |
| March 31, 2025 | 0.1369 |
| December 31, 2024 | 0.0864 |
| September 30, 2024 | 0.0917 |
| Date | Value |
|---|---|
| June 30, 2024 | 0.0775 |
| March 31, 2024 | 0.1013 |
| December 31, 2023 | 0.0721 |
| September 30, 2023 | 0.1088 |
| June 30, 2023 | 0.0752 |
| March 31, 2023 | 0.063 |
| December 31, 2022 | 0.1277 |
| September 30, 2022 | 0.0519 |
| June 30, 2022 | 0.2183 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| NovelStem International Corp. | -0.8748 |
| Brainstorm Cell Therapeutics, Inc. | -0.1185 |
| Summit Therapeutics, Inc. | 0.0354 |
| Kezar Life Sciences, Inc. | 0.0208 |
| Protara Therapeutics, Inc. | 0.0173 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 263.68M |
| Total Liabilities (Quarterly) | 361.92M |
| Shareholders Equity (Quarterly) | -98.25M |
| Current Ratio | 3.051 |
| Net Debt Paydown Yield | -0.09% |